A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, phase II clinical study in subjects with chronic
hepatitis B (CHB), to characterize the safety, tolerability, pharmacokinetic profile and
preliminary anti-hepatitis B virus (HBV) efficacy of APG-1387 in combination with entecavir,
and to determine the optimal dose of APG-1387 in combination with entecavir.